Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: Correlation with markers of disease activity

American Journal of Hematology

Volumn 72, Issue 4, 2003, Pages 229-233

  Alexandrakis, Michael G ^a   Passam, F H ^c   Sfiridaki, A ^b   Kandidaki, E ^b   Roussou, P ^c   Kyriakou, D S ^d  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b Venizelion General Hospital   (Greece)

^c SOTIRIA GENERAL HOSPITAL   (Greece)

^d University Hospital of Thessalia   (Greece)

Author keywords

Hepatocyte growth factor; Multiple myeloma; N telopeptide; Osteocalcin

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; BETA GLOBULIN; C REACTIVE PROTEIN; CALCIUM; COLLAGEN DERIVATIVE; COLLAGEN TYPE 1; INTERLEUKIN 6; OSTEOCALCIN; SCATTER FACTOR; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE LESION; BONE METABOLISM; BONE RADIOGRAPHY; BONE TURNOVER; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; FEMALE; HUMAN; MALE; MULTIPLE MYELOMA; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; SCORING SYSTEM;

ADULT; AGED; AGED, 80 AND OVER; BETA 2-MICROGLOBULIN; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CALCIUM; COLLAGEN; COLLAGEN TYPE I; FEMALE; HEPATOCYTE GROWTH FACTOR; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM PROTEINS; OSTEOCALCIN; OSTEOCLASTS; OSTEOLYSIS; PEPTIDES; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037381271     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.10304     Document Type: Article

References (26)

1. Nakamura T, Nawa K, Ichihara A. Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem Biophys Res Commun 1984;122:1450-1459.
2. Bussolino F, Di Renzo MF, Ziche M, Bocchietto E, Olivero M, Naldini L, Gaudino G, Tamagnone L, Loffer A, Comoglio PM. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 1992;119:629-641.
3. Stoker M, Gherardi E, Perryman M, Gray J. Scatter factor is a fibroblast-derived modulator of epithelium cell mobility. Nature 1987;327:239-242.
4. Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Van de Woude GF, Aaranson SA. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991;251:802-804.
5. Borset M, Lien E, Espevik T, Helseth E, Waage A, Sundan A. Concomitant expression of hepatocyte growth factor and the receptor c-met in human myeloma cell lines. J Biol Chem 1996;271:24655-24661.
6. Borset M, Hjorth-Hansen H, Seidel C, Sundan A, Waage A. Hepatocyte growth factor and its receptor c-met in multiple myeloma. Blood 1996;88:3998-4004.
7. Sato T, Hakeda Y, Yamaguchi Y, Mano H, Tezuka J, Sumitani K, Matsumoto K, Nakamura T, Mori Y, Yoshizama K. Hepatocyte growth factor is involved in formation of osteoclast-like cells mediated by clonal stromal cells (MC3T3-G2/PA6). J Cell Physiol 1995;164:197-204.
8. Grano M, Galimi F, Zambonin G, Colucci S, Cottone E, Zallone AZ, Comoglio PM. Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro. Proc Natl Acad Sci USA 1996;93:7644-7648.
9. Fuller K, Owens J, Chambers TJ. The effect of hepatocyte growth factor on the behavior of osteoclasts. Biochem Biophys Res Commun 1995;212:334-340.
10. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 1975;36:842-854.
11. Jiang W, Puntis MC, Nakamura T, Hallet MB. Neutrophil priming by hepatocyte growth factor, a novel cytokine. Immunology 1992;77:147-149.
12. Roodman GD. Interleukin-6: an osteotropic factor? Bone Miner Res 1992;7:475-478.
13. Tamura M, Arakaki N, Tsubouchi H, Takada H, Daikuhara Y. Enhancement of human hepatocyte growth factor production by interleukin-1α and -1β and tumor necrosis factor-α by fibroblasts in culture. J Biol Chem 1993;268:8140-8145.
14. Seider C, Borset M, Turesson I, Abeldgaard N, Sundan A, Waage A. Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. Blood 1998;91:806-812.
15. Mundy GR. Myeloma bone disease. Eur J Cancer 1996;34:246-251.
16. Roodman GD. Cell biology of the osteoclasts. Exp Hematol 1999;27:1229-1241.
17. Carter A, Merchav S, Silvian-Draxler I, Tatarsky I. The role of interleukin-1 and tumor necrosis factor-α in multiple myeloma. Br J Haematol 1990;74:424-431.
18. Bataille R, Jourdan M, Zhang X-G, Klein B. Serum levels of interleukin-6, a potent myeloma cell growth factor as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest 1989;84:2008-2011.
19. Pelliniemi TT, Irjala K, Mattila K, Pulkki K, Rajamaki A, Tienhaara A, Laakso M, Lahtinen R. Immunoreactive interleukin-6 and acute phase proteins a prognostic factor in multiple myeloma Finnish Leukemia Group. Blood 1995;85:765-771.
20. Sezer O, Jacob C, Eucher J, Niemoller K, Gatz F, Wernecke K-D, Possinger K. Serum levels of the angiogenic cytokines basic fibroblast growth factor (BFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma. Eur J Haematol 2001;66:83-88.
21. Bataille R, Chappard D, Basle M. Excessive bone resorption in human plasmacytomas: direct induction by tumor cells in vivo. Br J Haematol 1995;90:721-724.
22. Klein B, Bataille R. Cytokine network in human multiple myeloma. Hematol Oncol Clin North Am 1992;6:273-284.
23. Hanson DH, Weis MA, Bollen AM, Mastan SL, Singer FR, Eyre DR. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 1992;7:1251-1258.
24. Schneider DL, Barrett-Connor EL. Urinary N-telopeptide levels discriminate normal osteopenic and osteoporotic bone mineral density. Arch Intern Med 1997;157:1241-1245.
25. Carlson K, Ljunghall S, Simonsson B, Smedmyr B. Serum osteocalcin concentrations in patients with multiple myeloma - correlation with the disease stage and survival. J Intern Med 1992;231:133-137.
26. Bataille R, Delmas PD, Chappard D, Sany I. Abnormal serum bone gla protein levels in multiple myeloma: crucial role of bone formation and prognostic implications. Cancer 1990;66:167-172.